Traded Nov 17 – Nov 18, 2026 · largest single transaction ~$89K
Lately at Trisalus Life Sciences: the stock fell 19% in one session on Nov 11 around a company release; it reported its results on Nov 10; the stock is down 37% in 30 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Checked for new insider filings 54 min ago
Guides: What is an SEC Form 4 · the transaction codes · who has to file · 10b5-1 plans
Worth a look: purchases of $10K+ and sales of $250K+ not reported under a pre-arranged trading plan.
Traded Nov 17 – Nov 18, 2026 · largest single transaction ~$89K
Lately at Trisalus Life Sciences: the stock fell 19% in one session on Nov 11 around a company release; it reported its results on Nov 10; the stock is down 37% in 30 days.
Nov 18, 2026~$89K · 34K sh @ $2.59
DetailsOfficial recordNov 17, 2026~$71K · 31K sh @ $2.31
DetailsOfficial recordInsider buying
Traded Nov 17 · filed 2 days later
Since the trade −0.3% · S&P 500 −5.8% · to Nov 20
An Orion180 Insurance director paid $99K out of pocket for Orion180 Insurance shares. 1 other person at Orion180 Insurance bought some too, in the same month. Shares held went up 2922% with this purchase.
Lately at Orion180 Insurance Group: it reported its results on Nov 10; the stock is up 12% in 30 days; insiders made 6 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Traded Sep 22 – Sep 24, 2026 · largest single transaction ~$231K
Lately at Bioaffinity Technologies: it changed its bylaws, charter or fiscal year on Nov 20; the stock is down 54% in 30 days; insiders made 10 purchases ($10K+) and 1 large sale ($250K+, not pre-arranged) in 90 days.
Sep 24, 2026~$231K · 30K sh @ $7.67
DetailsOfficial recordSep 22, 2026~$163K · 19K sh @ $8.59
DetailsOfficial recordInsider buying
3 insiders in a week, 8th time since 2006Traded Nov 17 · filed 2 days later
Since the trade +6.8% · S&P 500 −5.8% · to Nov 20
Bought 68% below the 52-week high, RSI 42, 45% under its 200-day average, 31 points behind the S&P 500 over 3 months
A Stereotaxis director paid $25K out of pocket for Stereotaxis shares. 2 other people at Stereotaxis bought some too, in the same month. It was the first purchase in over a year.
Lately at Stereotaxis: it signed an important agreement on Nov 10; the stock is down 5% in 30 days; insiders made 3 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Traded Nov 18, 2026 · largest single transaction ~$787K
Lately at Atlassian: the stock fell 16% in one session on Nov 6 around a company release; it changed a top executive or board member on Nov 5; the stock is down 40% in 30 days.
Nov 18, 2026~$787K · 5,542 sh @ $142.00
DetailsOfficial recordNov 18, 2026~$428K · 3,038 sh @ $140.96
DetailsOfficial recordInsider buying
Open-market purchases, traded Nov 16 – Nov 18, 2026. Each amount is that person's own.
Lately at Tecogen: the stock fell 15% in one session on Oct 30; it reported its results on Nov 12; the stock is down 29% in 30 days.
Insider buying
Traded Nov 18 · filed 1 day later
Since the trade −5.2% · S&P 500 −5.5% · to Nov 20
An Arko Petroleum director paid $279K out of pocket for Arko Petroleum shares. Shares held went up 199% with this purchase.
Lately at Arko Petroleum: it completed buying or selling a business or assets on Nov 12; the stock is down 17% in 30 days; insiders made 1 purchase ($10K+) and 1 large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
First buy since 2018Traded Nov 18 · filed 1 day later
Since the trade +1.9% · S&P 500 −5.5% · to Nov 20
Bought within 2% of the 52-week low, RSI 36, 15% under its 200-day average, 16 points behind the S&P 500 over 3 months
Ellington Financial's Co-Chief Investment Officer paid $1.08M out of pocket for Ellington Financial shares. 1 other person at Ellington Financial bought some too, in the same month.
Lately at Ellington Financial, Inc.: it reported its results on Nov 4; insiders made 3 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
Traded Sep 14 · filed 66 days later
Since the trade −43.2% · S&P 500 −9.3% · to Nov 20
An Eltek director paid $1.52M out of pocket for Eltek shares.
Lately at Eltek: the stock is down 23% in 30 days; insiders made 18 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
4 insiders in a week, 6th time since 2006Traded Nov 18 · filed 1 day later
Since the trade −3.4% · S&P 500 −5.5% · to Nov 20
Bought at the 52-week low, RSI 26, 77% under its 200-day average, 73 points behind the S&P 500 over 3 months
A Perspective Therapeutics director paid $12K out of pocket for Perspective Therapeutics shares. 4 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 28% with this purchase.
Lately at Perspective Therapeutics: the stock fell 29% in one session on Oct 23 around a company release; it reported its results on Nov 9; the stock is down 67% in 30 days.
Insider buying
Traded Nov 17 · filed 2 days later
Since the trade −7.4% · S&P 500 −5.8% · to Nov 20
Bought 6% below the 52-week high, RSI 60, 17% above its 200-day average
An Advanced Flower Capital director paid $168K out of pocket for Advanced Flower Capital shares. 2 other people at Advanced Flower Capital bought some too, in the same month.
Lately at Advanced Flower Capital: the stock rose 14% in one session on Nov 17 with press coverage; it reported its results on Nov 5; the stock is up 9% in 30 days.
Insider buying
First insider buy on recordTraded Nov 17 · filed 2 days later
Since the trade −5.5% · S&P 500 −5.8% · to Nov 20
Bought at the 52-week low, RSI 29, 63% under its 200-day average, 60 points behind the S&P 500 over 3 months
An USA Rare Earth director paid $1.66M out of pocket for USA Rare Earth shares.
Lately at USA Rare Earth: the stock rose 17% in one session on Oct 27 with press coverage; it reported its results on Nov 9; the stock is down 39% in 30 days.
Insider buying
Traded Nov 18 · filed 1 day later
Since the trade −0.5% · S&P 500 −5.5% · to Nov 20
The CEO of Hmh paid $88K out of pocket for Hmh shares. 1 other person at Hmh bought some too, in the same month. Shares held went up 6% with this purchase.
Lately at Hmh Holding: the stock fell 22% in one session on Nov 5 around a company release; it reported its results on Nov 4; the stock is down 39% in 30 days.
Insider buying
Traded Nov 18 · filed 1 day later
Since the trade +1.2% · S&P 500 −5.5% · to Nov 20
Bought at the 52-week low, RSI 29, 23% under its 200-day average, 22 points behind the S&P 500 over 3 months
The CEO of Dynex Capital paid $50K out of pocket for Dynex Capital shares. 2 other people at Dynex Capital bought some too, in the same month.
Lately at Dynex Capital: it reported its results on Oct 19; the stock is down 11% in 30 days; insiders made 8 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
First insider buy since Mar 2023Traded Nov 18 · filed 1 day later
Since the trade −1.0% · S&P 500 −5.5% · to Nov 20
Bought at the 52-week low, RSI 31, 42% under its 200-day average, 16 points behind the S&P 500 over 3 months
A Coastal Financial director paid $188K out of pocket for Coastal Financial shares. Shares held went up 19% with this purchase.
Lately at Coastal Financial: it changed a top executive or board member on Oct 29; the stock is down 15% in 30 days; insiders made 2 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.
Insider buying
Traded Nov 19 · filed the same day
Since the trade +3.7% · S&P 500 −3.6% · to Nov 20
Bought within 2% of the 52-week low, RSI 24, 33% under its 200-day average, 27 points behind the S&P 500 over 3 months
A Pedevco director paid $49K out of pocket for Pedevco shares. 1 other person at Pedevco bought some too, in the same month. Shares held went up 22% with this purchase.
Lately at Pedevco: the stock fell 12% in one session on Nov 17 with press coverage; it reported its results on Nov 13; the stock is down 35% in 30 days.